Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2009-08-05 Capital/Financing Update
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Appendix 3B (Amended) and Cleansing Statement 11 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and related agreements. It details the issuance of ordinary shares and listed options, including the number of securities, issue price, purpose, and quotation details. It also includes a relief notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of securities without disclosure. The document is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital raising event and securities quotation application. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issuance and quotation, confirming it is not merely an announcement of a report but the actual filing of the capital raising event.
2009-08-05 English
Appendix 3B and Cleansing Statement 8 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcing new issues of securities, applications for quotation of additional securities, and related agreements. It details the class and number of securities issued, terms, issue price, purpose of the issue, and compliance with the Corporations Act. It also includes a relief notice under section 708A(5)(e) of the Corporations Act regarding the issue of securities without disclosure. The content is focused on capital raising and securities issuance rather than financial results, management changes, or other report types. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report but a substantive filing about capital changes.
2009-08-04 English
Reinstatement to Official Quotation 1 page ?Kb
Regulatory Filings
2009-07-29 English
Share Placement 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 30 July 2009 from Living Cell Technologies Limited regarding a private placement of shares raising A$4.2 million to fund clinical trials. It details the share issue price, number of shares and options issued, and the intended use of funds. There is no financial statement or detailed financial analysis present, nor is this a report or transcript. The content focuses on a capital raising event and share issuance. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length is about 5,459 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is CAP with high confidence.
2009-07-29 English
Appendix 4C - quarterly 7 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow report to 30 June 2009' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities. It provides financial data for the quarter ended 30 June 2009, including cash balances, cash flows, and payments to directors. The document is a comprehensive quarterly financial report with substantive financial data and analysis, not merely an announcement or certification. The presence of detailed cash flow statements and quarterly period references aligns with the definition of an Interim / Quarterly Report (IR). Q4 2009
2009-07-29 English
Suspension from Official Quotation 2 pages ?Kb
Regulatory Filings
2009-07-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.